Last reviewed · How we verify
Omegaven 10%
At a glance
| Generic name | Omegaven 10% |
|---|---|
| Also known as | fish oil, N-3 polyunsaturated fatty acids atty acids, Arm 2 |
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients (PHASE2)
- Cholestasis Reversal: Efficacy of IV Fish Oil (PHASE2, PHASE3)
- Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis (PHASE2)
- Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury (PHASE2)
- Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis (NA)
- Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients (NA)
- Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
- Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omegaven 10% CI brief — competitive landscape report
- Omegaven 10% updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI